Virax Biolabs Group Limited filed an 8-K press release on October 29, 2026, announcing three new non-exclusive distributor agreements in mainland China for its ImmuneSelect research-use-only immune profiling products, entered through its China subsidiary Shanghai Xitu Consulting Co., Ltd.

Key Highlights

  • Three new distributors: AmyJet Scientific Inc., Jiangsu Real-Gen Biotechnology Co., Ltd., and Zhixi (Shanghai) Biotechnology Co., Ltd. have each signed non-exclusive distribution agreements for ImmuneSelect products.
  • Six mainland Chinese provinces and cities covered: The agreements span authorized markets across Beijing, Shanghai, Hubei, Jiangsu, Anhui, and Shandong, according to the filing.
  • Product focus: The initial product scope is ELISpot assay plates and antigen-specific peptide pools for infectious disease, vaccine, and cellular immunity research, the company disclosed.
  • AmyJet's scope: AmyJet, which reports more than 200 international life sciences supplier relationships, will target industrial and biotechnology customers in Beijing, Shanghai, and Hubei.
  • Jiangsu Real-Gen's scope: Jiangsu Real-Gen, with regional presence in Suzhou, Nanjing, Hefei, and Jinan, will target academic, biopharmaceutical, and other research customers in Jiangsu, Anhui, and Shandong.
  • Zhixi's role: Zhixi adds a targeted Shanghai academic sales channel and is under common ownership with Shanghai KEL Biotech, according to the filing.
  • Separate from ViraxImmune: The filing states ImmuneSelect is distinct from ViraxImmune, the company's in-development diagnostic platform.

Virax Expands China Commercial Reach via Three Non-Exclusive Distributor Appointments

According to the filing, Virax Biolabs Group Limited (NASDAQ:VRAX) entered into the three agreements through its China subsidiary, Shanghai Xitu Consulting Co., Ltd. The company disclosed that the appointments build on initial ImmuneSelect product sales from its existing mainland China operations and complement a previously announced exclusive commercial supply agreement with Fosun Diagnostics across six Southeast Asian markets. Under each agreement, the distributors will purchase ImmuneSelect products from Virax for resale within their respective authorized markets and customer segments, with the distributors managing local sales, customer engagement, and customer training.

The filing notes that the covered territories include major Chinese biotechnology centers such as Beijing's Zhongguancun Life Science Park, Shanghai's Zhangjiang Pharma Valley, Suzhou's BioBAY, and Wuhan's BioLake. The company also referenced a Suzhou Industrial Park report that BioBAY alone hosts more than 600 biomedical enterprises, describing this as illustrative of "the scale of one of the research markets Virax intends to address." Virax stated it will provide product supply, documentation, and technical support under the arrangements.

James Foster, Chairman and Chief Executive Officer of Virax Biolabs, stated in the release: "These appointments allow us to reach prospective customers through established local distribution networks, with the objective of converting product evaluations into orders and building recurring reagent sales." He added that the company intends to pursue the China opportunity "while maintaining a disciplined, capital-efficient commercial model." The filing contains forward-looking statements, which the company cautioned are subject to risks including the possibility that the China distribution agreements may not generate anticipated orders or revenues and that customer evaluations may not result in commercial adoption.

What Was Disclosed

Virax Biolabs announced three non-exclusive distributor agreements for its ImmuneSelect research-use-only products across six mainland Chinese markets, entered through its Shanghai subsidiary, with each distributor responsible for local sales, customer engagement, and training.